Smith & Nephew plc (LON:SN) Given Consensus Recommendation of “Hold” by Analysts

Shares of Smith & Nephew plc (LON:SN) have received a consensus recommendation of “Hold” from the eight research firms that are covering the stock, Marketbeat reports. Five analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is GBX 1,382.62.

Several equities analysts have recently issued reports on the stock. UBS Group reaffirmed a “neutral” rating and issued a GBX 1,300 price objective on shares of Smith & Nephew in a research note on Tuesday, May 5th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a GBX 1,400 target price on shares of Smith & Nephew in a research note on Thursday, June 11th. Jefferies Financial Group restated a “buy” rating and set a GBX 2,760 target price on shares of Smith & Nephew in a report on Thursday, May 21st. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a GBX 1,350 price target on shares of Smith & Nephew in a report on Monday. Finally, Berenberg Bank reiterated a “hold” rating and set a GBX 13 price objective on shares of Smith & Nephew in a research report on Friday, May 1st.

Smith & Nephew Trading Up 2.9%

Shares of Smith & Nephew stock opened at GBX 1,126.50 on Friday. The company has a current ratio of 2.57, a quick ratio of 0.84 and a debt-to-equity ratio of 62.90. The business has a 50 day simple moving average of GBX 1,132.35 and a 200-day simple moving average of GBX 1,208. The company has a market capitalization of £12.35 billion, a PE ratio of 40.56, a PEG ratio of 0.46 and a beta of 0.67.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.